Pamrevlumab
Monoclonal antibody
- none
- 946415-13-0
- none
- QS5F6VTS0O
- D10969
Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.[2]
This drug was developed by FibroGen, Inc.[3]
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID 32447983. S2CID 218873298.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
- v
- t
- e